Ligand validation:1JU9

NAD: NICOTINAMIDE-ADENINE-DINUCLEOTIDE

NAD is a Ligand Of Interest in 1JU9 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
1JU9_NAD_B_377	16%	38%	0.173	0.809	0.99	1.41	2	3	0	0	61%	0.6136
1JU9_NAD_A_377	12%	36%	0.177	0.774	1.04	1.47	2	2	0	0	61%	0.6136
1HET_NAD_A_402	100%	10%	0.043	0.994	2.25	2.1	9	8	0	0	100%	0.9068
2JHF_NAD_B_403	100%	16%	0.04	0.99	2.08	1.62	11	5	2	0	100%	1
1HEU_NAD_B_402	100%	7%	0.043	0.993	2.5	2.41	13	11	0	0	100%	0.8886
2JHG_NAD_B_403	100%	21%	0.043	0.991	1.51	1.76	7	7	0	0	100%	0.8909
1HF3_NAD_A_402	99%	6%	0.057	0.987	2.38	2.69	18	21	1	0	100%	0.9068
3CMC_NAD_R_408	100%	20%	0.016	0.998	1.63	1.74	4	9	0	0	100%	1
3EC7_NAD_A_400	100%	18%	0.025	0.995	1.8	1.74	5	8	1	0	100%	1
4URF_NAD_A_1249	100%	44%	0.034	0.995	0.96	1.2	2	4	0	0	100%	1
2C5A_NAD_B_1374	100%	23%	0.039	0.992	1.34	1.84	6	7	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.